Pulmonx Corporation (NASDAQ:LUNG) Given Average Recommendation of “Hold” by Brokerages

Pulmonx Corporation (NASDAQ:LUNG) has been assigned a consensus recommendation of “Hold” from the ten research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $6.8071.

LUNG has been the subject of a number of research analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $14.00 target price on shares of Pulmonx in a research note on Thursday, November 13th. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmonx in a research report on Wednesday, October 8th. Finally, Lake Street Capital reduced their price objective on Pulmonx from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, October 28th.

Institutional Investors Weigh In On Pulmonx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vestal Point Capital LP bought a new position in shares of Pulmonx in the third quarter worth about $1,345,000. Bank of America Corp DE grew its stake in shares of Pulmonx by 556.6% during the second quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock valued at $1,246,000 after purchasing an additional 407,971 shares during the last quarter. Parkman Healthcare Partners LLC increased its holdings in shares of Pulmonx by 194.4% in the first quarter. Parkman Healthcare Partners LLC now owns 611,875 shares of the company’s stock valued at $4,118,000 after purchasing an additional 404,022 shares in the last quarter. GSA Capital Partners LLP raised its position in Pulmonx by 78.3% in the 3rd quarter. GSA Capital Partners LLP now owns 755,467 shares of the company’s stock worth $1,224,000 after purchasing an additional 331,742 shares during the last quarter. Finally, Nuveen LLC acquired a new position in Pulmonx during the 1st quarter worth $1,336,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Stock Performance

Shares of NASDAQ:LUNG opened at $1.75 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.86 and a quick ratio of 4.15. The business’s fifty day moving average price is $1.68 and its two-hundred day moving average price is $2.16. Pulmonx has a fifty-two week low of $1.31 and a fifty-two week high of $9.37. The stock has a market capitalization of $72.19 million, a price-to-earnings ratio of -1.24 and a beta of 0.22.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. Pulmonx had a negative return on equity of 77.58% and a negative net margin of 61.91%.The company had revenue of $21.50 million during the quarter, compared to analysts’ expectations of $20.78 million. As a group, analysts predict that Pulmonx will post -1.55 EPS for the current fiscal year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.